Fiona M. Fennessy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fiona M. Fennessy has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Clare Tempany
Brigham and Women's Hospital, Boston, MA
8 shared publications Adam S. Kibel
Department of Urology, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA
2 shared publications- Alexander Putnam Cole
Brigham and Women’s Hospital
2 shared publications - Begoña Giménez
Departamento de Ciencia y Tecnología de los Alimentos, Facultad Tecnológica, Universidad de Santiago de Chile, Av. Víctor Jara 3769, Estación Central, Santiago 9170124, Chile
2 shared publications Camden Bay
Department of Radiology, Harvard Medical School, Brigham and Women’s Hospital, Boston, USA
2 shared publicationsCarl-Fredrik Westin
Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
2 shared publications
Latest Publications
- 19 January 2024
- Published by Elsevier in Clinical Radiology
- Vol. 79 (4) , e607-e615
Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer
- 19 January 2024
- Published by Elsevier in Clinical Radiology
- Vol. 79 (4) , e607-e615
Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer
- 1 September 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (9) , e220100
Local Staging of Prostate Cancer at MRI: What the Urologist and Radiation Oncologist Want to Know
- 1 September 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (9) , e220100
Local Staging of Prostate Cancer at MRI: What the Urologist and Radiation Oncologist Want to Know
- 25 August 2023
- Published by Elsevier in European Journal of Radiology
- Vol. 167, 111066
Quantitative diffusion MRI in prostate cancer: Image quality, what we can measure and how it improves clinical assessment
- 25 August 2023
- Published by Elsevier in European Journal of Radiology
- Vol. 167, 111066
Quantitative diffusion MRI in prostate cancer: Image quality, what we can measure and how it improves clinical assessment
- 1 June 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (6) , e220212
Invited Commentary: Pelvic MRI Is Now the Basis of Personalized Fibroid Care
- 1 June 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (6) , e220212
Invited Commentary: Pelvic MRI Is Now the Basis of Personalized Fibroid Care
- 18 May 2023
- Published by Elsevier in Academic Radiology
- Vol. 30 (11) , 2761-2768
Practical Tips and a Template for Developing Your Curriculum Vitae
- 18 May 2023
- Published by Elsevier in Academic Radiology
- Vol. 30 (11) , 2761-2768
Practical Tips and a Template for Developing Your Curriculum Vitae
- Open Access
- 11 April 2023
- Published by Wiley in BJUI Compass
- Vol. 4 (4) , 473-481
PI‐RADS 3 score: A retrospective experience of clinically significant prostate cancer detection
Rationale and objectives: The study aims to propose an optimal workflow in patients with a PI‐RADS 3 (PR‐3) assessment category (AC) through determining the timing and type of pathology interrogation used for the detection of clinically significant prostate cancer (csPCa) in these men based upon a 5‐year retrospective review in a large academic medical center.Materials and methods: This United States Health Insurance Probability and Accountability Act (HIPAA)‐compliant, institutional review board‐approved retrospective study included men without prior csPCa diagnosis who received PR‐3 AC on magnetic resonance (MR) imaging (MRI). Subsequent incidence and time to csPCa diagnosis and number/type of prostate interventions was recorded. Categorical data were compared using Fisher's exact test and continuous data using ANOVA omnibus F‐test.Results: Our cohort of 3238 men identified 332 who received PR‐3 as their highest AC on MRI, 240 (72.3%) of whom had pathology follow‐up within 5 years. csPCa was detected in 76/240 (32%) and non‐csPCa in 109/240 (45%) within 9.0 ± 10.6 months. Using a non‐targeted trans‐rectal ultrasound biopsy as the initial approach (n = 55), another diagnostic procedure was required to diagnose csPCa in 42/55 (76.4%) of men, compared with 3/21(14.3%) men with an initial MR targeted‐biopsy approach (n = 21); (p < 0.0001). Those with csPCa had higher median serum prostate‐specific antigen (PSA) and PSA density, and lower median prostate volume (p < 0.003) compared with non‐csPCa/no PCa.Conclusion: Most patients with PR‐3 AC underwent prostate pathology exams within 5 years, 32% of whom were found to have csPCa within 1 year of MRI, most often with a higher PSA density and a prior non‐csPCa diagnosis. Addition of a targeted biopsy approach initially reduced the need for a second biopsy to reach a for csPCa diagnosis. Thus, a combination of systematic and targeted biopsy is advised in men with PR‐3 and a co‐existing abnormal PSA and PSA density.
- 11 April 2023
- Published by Wiley in BJUI Compass
- Vol. 4 (4) , 473-481
Open AccessPI‐RADS 3 score: A retrospective experience of clinically significant prostate cancer detection
Rationale and objectives: The study aims to propose an optimal workflow in patients with a PI‐RADS 3 (PR‐3) assessment category (AC) through determining the timing and type of pathology interrogation used for the detection of clinically significant prostate cancer (csPCa) in these men based upon a 5‐year retrospective review in a large academic medical center.Materials and methods: This United States Health Insurance Probability and Accountability Act (HIPAA)‐compliant, institutional review board‐approved retrospective study included men without prior csPCa diagnosis who received PR‐3 AC on magnetic resonance (MR) imaging (MRI). Subsequent incidence and time to csPCa diagnosis and number/type of prostate interventions was recorded. Categorical data were compared using Fisher's exact test and continuous data using ANOVA omnibus F‐test.Results: Our cohort of 3238 men identified 332 who received PR‐3 as their highest AC on MRI, 240 (72.3%) of whom had pathology follow‐up within 5 years. csPCa was detected in 76/240 (32%) and non‐csPCa in 109/240 (45%) within 9.0 ± 10.6 months. Using a non‐targeted trans‐rectal ultrasound biopsy as the initial approach (n = 55), another diagnostic procedure was required to diagnose csPCa in 42/55 (76.4%) of men, compared with 3/21(14.3%) men with an initial MR targeted‐biopsy approach (n = 21); (p < 0.0001). Those with csPCa had higher median serum prostate‐specific antigen (PSA) and PSA density, and lower median prostate volume (p < 0.003) compared with non‐csPCa/no PCa.Conclusion: Most patients with PR‐3 AC underwent prostate pathology exams within 5 years, 32% of whom were found to have csPCa within 1 year of MRI, most often with a higher PSA density and a prior non‐csPCa diagnosis. Addition of a targeted biopsy approach initially reduced the need for a second biopsy to reach a for csPCa diagnosis. Thus, a combination of systematic and targeted biopsy is advised in men with PR‐3 and a co‐existing abnormal PSA and PSA density.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1-S4, Table S1 from Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging
S1. Segmentation map of a subset of lower Gleason tissue specimens, demonstrates regional differences between tumor and normal tissue, and between the two different Gleason grades S2. Example MALDI ion images of 2 long chain acylcarnitine species S3. Annotated H&E and serial frozen sections of human prostate tissue S4. Scores plot from PLSDA multivariate analysis of LESA MS data from tumor and normal prostate tissue Table 1. Pathological description of specimens used for MALDI MSI, cases were staged according to AJCC TNM 8th edition
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1-S4, Table S1 from Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging
S1. Segmentation map of a subset of lower Gleason tissue specimens, demonstrates regional differences between tumor and normal tissue, and between the two different Gleason grades S2. Example MALDI ion images of 2 long chain acylcarnitine species S3. Annotated H&E and serial frozen sections of human prostate tissue S4. Scores plot from PLSDA multivariate analysis of LESA MS data from tumor and normal prostate tissue Table 1. Pathological description of specimens used for MALDI MSI, cases were staged according to AJCC TNM 8th edition
- Open Access
- 17 March 2023
- Published by Springer Nature
- p. 177-187
Benign Disease of the Uterus
Benign diseases of the uterus are common and typically present with disordered menstrual bleeding and pain. The first-line imaging investigation is pelvic ultrasound which readily demonstrates abnormal features within the myometrium and endometrium. Ultrasound examination demonstrates fibroids, adenomyosis, endometrial polyps and is also first-line imaging for endometriosis. MR examination is focused on addressing a particular question, e.g., assessment prior to fibroid embolization or mapping of endometriosis prior to surgical resection. Congenital anomalies of the uterus are important to define as intervention can lead to future successful pregnancy outcomes, e.g., resection of septum and imaging will also demonstrate associated renal anomalies. Optimal imaging sequences and planes allow the radiologist to accurately determine key characteristic features.
- 17 March 2023
- Published by Springer Nature
- p. 177-187
Open AccessBenign Disease of the Uterus
Benign diseases of the uterus are common and typically present with disordered menstrual bleeding and pain. The first-line imaging investigation is pelvic ultrasound which readily demonstrates abnormal features within the myometrium and endometrium. Ultrasound examination demonstrates fibroids, adenomyosis, endometrial polyps and is also first-line imaging for endometriosis. MR examination is focused on addressing a particular question, e.g., assessment prior to fibroid embolization or mapping of endometriosis prior to surgical resection. Congenital anomalies of the uterus are important to define as intervention can lead to future successful pregnancy outcomes, e.g., resection of septum and imaging will also demonstrate associated renal anomalies. Optimal imaging sequences and planes allow the radiologist to accurately determine key characteristic features.
- Open Access
- 30 June 2022
- Published by Springer Nature in European Radiology
- Vol. 33 (1) , 461-471
Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship
Objectives: The Prostate Imaging Quality (PI-QUAL) score is a new metric to evaluate the diagnostic quality of multiparametric magnetic resonance imaging (MRI) of the prostate. This study assesses the impact of an intervention, namely a prostate MRI quality training lecture, on the participant’s ability to apply PI-QUAL. Methods: Sixteen participants (radiologists, urologists, physicists, and computer scientists) of varying experience in reviewing diagnostic prostate MRI all assessed the image quality of ten examinations from different vendors and machines. Then, they attended a dedicated lecture followed by a hands-on workshop on MRI quality assessment using the PI-QUAL score. Five scans assessed by the participants were evaluated in the workshop using the PI-QUAL score for teaching purposes. After the course, the same participants evaluated the image quality of a new set of ten scans applying the PI-QUAL score. Results were assessed using receiver operating characteristic analysis. The reference standard was the PI-QUAL score assessed by one of the developers of PI-QUAL. Results: There was a significant improvement in average area under the curve for the evaluation of image quality from baseline (0.59 [95 % confidence intervals: 0.50–0.66]) to post-teaching (0.96 [0.92–0.98]), an improvement of 0.37 [0.21–0.41] (p < 0.001). Conclusions: A teaching course (dedicated lecture + hands-on workshop) on PI-QUAL significantly improved the application of this scoring system to assess the quality of prostate MRI examinations. Key Points: • A significant improvement in the application of PI-QUAL for the assessment of prostate MR image quality was observed after an educational intervention. • Appropriate training on image quality can be delivered to those involved in the acquisition and interpretation of prostate MRI. • Further investigation will be needed to understand the impact on improving the acquisition of high-quality diagnostic prostate MR examinations.
- 30 June 2022
- Published by Springer Nature in European Radiology
- Vol. 33 (1) , 461-471
Open AccessPromoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship
Objectives: The Prostate Imaging Quality (PI-QUAL) score is a new metric to evaluate the diagnostic quality of multiparametric magnetic resonance imaging (MRI) of the prostate. This study assesses the impact of an intervention, namely a prostate MRI quality training lecture, on the participant’s ability to apply PI-QUAL. Methods: Sixteen participants (radiologists, urologists, physicists, and computer scientists) of varying experience in reviewing diagnostic prostate MRI all assessed the image quality of ten examinations from different vendors and machines. Then, they attended a dedicated lecture followed by a hands-on workshop on MRI quality assessment using the PI-QUAL score. Five scans assessed by the participants were evaluated in the workshop using the PI-QUAL score for teaching purposes. After the course, the same participants evaluated the image quality of a new set of ten scans applying the PI-QUAL score. Results were assessed using receiver operating characteristic analysis. The reference standard was the PI-QUAL score assessed by one of the developers of PI-QUAL. Results: There was a significant improvement in average area under the curve for the evaluation of image quality from baseline (0.59 [95 % confidence intervals: 0.50–0.66]) to post-teaching (0.96 [0.92–0.98]), an improvement of 0.37 [0.21–0.41] (p < 0.001). Conclusions: A teaching course (dedicated lecture + hands-on workshop) on PI-QUAL significantly improved the application of this scoring system to assess the quality of prostate MRI examinations. Key Points: • A significant improvement in the application of PI-QUAL for the assessment of prostate MR image quality was observed after an educational intervention. • Appropriate training on image quality can be delivered to those involved in the acquisition and interpretation of prostate MRI. • Further investigation will be needed to understand the impact on improving the acquisition of high-quality diagnostic prostate MR examinations.